FM1000

FM1000 is an experimental surfactant studied as an excipient for stabilizing liquid formulations of therapeutic proteins. In the scientific literature, it is described as N-myristoyl phenylalanine-N-polyetheramine diamide, an amphiphilic molecule containing a hydrophobic tail, an amino-acid-derived segment, and a hydrophilic polyetheramine region. ([ACS Publications][1])

How FM1000 works at interfaces

Therapeutic proteins can adsorb at air/water, solid/liquid, and other interfaces encountered during preparation, processing, transport, storage, and administration. Interfacial adsorption can promote conformational changes, particle formation, and agitation-induced aggregation. As a surfactant, FM1000 competes for these interfaces: its hydrophobic portion associates with the interfacial region, while its hydrophilic portion remains exposed to the aqueous phase.

Studies using dynamic surface tension and interfacial adsorption measurements have shown that FM1000 can occupy and stabilize the air/water interface rapidly. In experimental comparisons with polysorbates and poloxamers, this fast adsorption behavior was associated with less opportunity for proteins to reach the interface and with reduced aggregation in agitation-stressed protein models. ([Publicações ACS][2])

Why FM1000 is relevant to biologic formulations

Scientific interest in FM1000 is closely related to the physical stability of antibodies and other proteins in solution. Surfactants are commonly investigated or used to reduce undesirable protein-surface interactions, but their performance cannot be predicted from critical micelle concentration or equilibrium surface tension alone. Adsorption rate, molecular area at the interface, adsorption reversibility, and the ability to compete with proteins are also important variables.

Published studies with immunoglobulin G, abatacept, and monoclonal antibodies have used FM1000 as a model next-generation surfactant to examine these mechanisms. Subsequent work also investigated structural variants of the same surfactant platform by changing hydrophobic tail length, allowing researchers to relate molecular structure to adsorption kinetics and protection against protein aggregation. ([Publicações ACS][2])

Related techniques and parameters

• Dynamic tensiometry: measures changes in surface tension over time and helps characterize surfactant adsorption kinetics.
• Interfacial adsorption: describes accumulation of molecules at an interface and their competition with proteins for available surface area.
• Critical micelle concentration (CMC): an important surfactant parameter, but not a stand-alone predictor of interfacial protein protection.
• Protein aggregation: can be monitored to determine whether interfacial protection reduces aggregate or particle formation under stress.

Limitations and interpretation

FM1000 is primarily described in the literature as a research surfactant or novel excipient. Results obtained with specific model proteins, concentrations, interfaces, and agitation protocols should not be generalized automatically to every biologic drug product. Excipient selection requires evaluation of chemical and physical stability, compatibility, safety, manufacturing conditions, container-closure interactions, and the regulatory requirements applicable to the final formulation.

Frequently asked questions about FM1000

Is FM1000 a polysorbate?

No. FM1000 has a different chemical architecture from polysorbates. It has been studied as an alternative surfactant for comparing interfacial behavior and protein stabilization.

What is the main function studied for FM1000?

The main investigated role is interfacial stabilization of protein formulations by limiting protein adsorption to surfaces and reducing aggregation associated with agitation.

Is FM1000 a routinely used pharmaceutical excipient?

The published literature describes FM1000 as a novel or experimental excipient. Performance reported in research studies should not be interpreted by itself as evidence of regulatory approval or routine use in commercial drug products.